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A B S T R A C T
HT61 is a small quinolone-derived compound previously demonstrated to exhibit bactericidal activity against gram-positive bacteria including methicillin-suscep-
tible Staphylococcus aureus (MSSA) and methicillin-resistant Staphylococcus aureus (MRSA). When combined with the classical antibiotics and antiseptics neomycin,
gentamicin, mupirocin and chlorhexidine, HT61 demonstrated synergistic bactericidal activity against both MSSA and MRSA infections in vitro. In this study, we
investigated the individual antimicrobial activity of HT61 alongside its capability to potentiate the eﬃcacy of tobramycin against both a tobramycin sensitive
laboratory reference strain (PAO1) and tobramycin resistant clinical isolates (RP73, NN2) of the gram-negative bacteria Pseudomonas aeruginosa (P. aeruginosa).
Using broth microdilution methods, the MICs of HT61 were assessed against all strains, as well as the eﬀect of HT61 in combination with tobramycin using both the
chequerboard method and bacterial time-kill assays. A murine model of pulmonary infection was also used to evaluate the combination therapy of tobramycin and
HT61 in vivo. In these studies, we demonstrated signiﬁcant synergism between HT61 and tobramycin against the tobramycin resistant P. aeruginosa strains RP73 and
NN2, whilst an additive/intermediate eﬀect was observed for P. aeruginosa strain PA01 which was further conﬁrmed using bacterial time kill analysis. In addition, the
enhancement of tobramycin by HT61 was also evident in in vitro assays of bioﬁlm eradication. Finally, in vivo studies revealed analogous eﬀects to those observed in
vitro with HT61 signiﬁcantly reducing bacterial load when administered in combination with tobramycin against each of the three P. aeruginosa strains at the highest
tested dose (10 mg/kg).
1. Introduction
Pseudomonas aeruginosa is a common pathogen that has been im-
plicated in both hospital and community-aquired infections. Of these
diﬀerent infections, one of the most clinically challenging is the chronic
airway infection by P. aeruginosa particuarly in individiuals with Cystic
Fibrosis (CF). During exacerbation of clinical symptoms, the ami-
noglycoside tobramycin is one of the most commonly used antibiotics
used in the treatment of P.aeruginosa infections [1–5]. Once established
as a bioﬁlm, P. aeruginosa infections are particularly recalcitrant to
eradication by tobramycin and other commerical antibiotics. The
complexitiy of this situation is further complicated by the existence of
many strains of P. aeruginosa which display resistance to one or more
antibioics, with tobramycin resistance a common occurrence [6,7]. The
resulting health care challenges that are faced by society in the treat-
ment of infectious diseases have been documented extensively [8,9]
and with few new classes of antibiotics on the horizon, new strategies
are urgently required that refresh or extend the impact of existing an-
tibiotics. One such approach to achieve this is in the identiﬁcation of
novel compounds with the capability to restore the sensitivity of ex-
isting antibiotics when used as combination therapies. Such drugs are
termed “enhancer compounds”.
The small quinolone-derived compound HT61, is one such molecule
that has previously demonstrated synergy with the aminoglycoside
antibiotics neomycin and gentamicin. In these studies, synergy was
observed against the gram-positive bacteria MRSA and MSSA in vitro
and in an in vivo model of murine skin infection [10]. Whilst HT61 has
been shown to enhance the activity of some antibiotics, it has also
demonstrated direct bactericidal activity against gram-positive bacteria
[11]. This bactericidal activity has been proposed to be a result of the
cationic charge of HT61 partitioning into the negatively charged bilayer
of the bacterial cell membrane causing structural changes and resulting
in a loss of membrane integrity and depolarisation. Ultimatley, this
severe membrane damage induces the expulsion of intracellular com-
ponents and eventually, cell death [12,13]. This direct bactericidal
activity of HT61 has previously been used as a topical agent and con-
tinues to advance through clinical trials with the ultimate aim of de-
colonising S. aureus from the nasal cavity [14].
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Despite this ongoing activity investigating the eﬀects of HT61 on
gram-positive bacteria, there have been no published studies that have
focused on the activity of HT61, either alone or in combination with
antibiotics against any gram-negative bacterial species. Our working
hypothesis was that, despite the diﬀerences in bacterial cell wall
structure between gram-negative and gram-positive bacterial species,
HT61 may continue to possess direct bactericidal activity and also en-
hance the activity of aminoglycoside antibiotics such as tobramycin
when used in combination against P. aeruginosa. In this study, the
ability of HT61 to enhance the antibacterial activity of tobramycin was
assessed against three diﬀerent strains (RP73, NN2 and PA01) of P.
aeruginosa; with each strain diﬀering in their tobramycin susceptibility
proﬁle. To this end, we combined conventional in vitro assays of bac-
tericidal activity such as the chequerboard assay, bacterial time-kill
assays and bioﬁlm eradication assays with an in vivo murine model of
pulmonary infection.
2. Materials and methods
2.1. Bacterial culture conditions and maintenance
All bacterial strains were stored at −80 °C using the CryoBead
system (TSC Ltd., Heywood, UK) and routinely maintained by using
Tryptone Soy Agar (TSA; Oxoid, Ltd. Basingstoke, UK). Three P. aeru-
ginosa strains were generously gifted from Dr Alessandra Bragonzi at
the Infection and Cystic Fibrosis Unit, San Raﬀaele Scientiﬁc Institute,
Milan, Italy. The fully sequenced tobramycin sensitive laboratory re-
ference strain PA01, a multi-drug resistant non-mucoid strain RP73
isolated 17.5 years post onset of infection in a CF patient (multidrug
resistant CF isolate) and NN2 a tobramycin resistant CF isolate collected
at the onset of chronic colonization (tobramycin resistant CF isolate)
[15,16]. For all susceptibility assays, Cation-Adjusted Mueller Hinton
(CAMH) broth was obtained from BD Diagnostics (Wokingham, UK) as
recommended previously [17]. For all in vivo studies, all strains were
grown on TSA and cultured in Nutrient broth (Oxoid) at 37 °C, 120 rpm.
2.2. Chemicals used in this study
All chemicals were purchased from Sigma Aldrich (Sigma-Aldrich,
Dorset, UK) unless stated otherwise. All in vitromaterials were sterilised
by autoclaving at 121 °C for 20 min. HT61-HCl was generously donated
by Professor Sir Anthony Coates, St Georges Hospital, London and
Helperby Therapeutics, and ﬁrst dissolved in DMSO (10 g/L). Stock
solutions were prepared by the addition of dH2O to 2.4 g/L prior to
sterilisation as eﬀected by 0.22 μm ﬁltration (Thermo Fisher Scientiﬁc,
Loughborough, UK). HT61 solutions were stored at −20 °C.
Tobramycin stocks were made in dH2O to give 10 g/L or 50 g/L
working concentrations that were sterilised by using ﬁltration at
0.22 μm. Solutions were stored at −20 °C.
2.3. Minimum inhibitory concentration (MIC) assay
MICs were determined according to the protocols described pre-
viously [17]. Serial twofold dilutions of tobramycin and HT61 were
prepared in distilled water in ﬂat well polycarbonate 96 well plates
(Greiner Bio-One Ltd, Stonehouse, UK). To each well, double strength
CAMH broth was added. Colonies from overnight incubation on CAMH
agar were resuspended in sterile saline and a concentration of
5 × 105 cfu/mL were inoculated. Plates were sealed with a “breathable
membrane” (Greiner Bio-One Ltd) and incubated in a wet chamber at
37 °C for 16–20 h. Bacterial load was measured by optical density at
600 nm by using a Fluostar Omega reader (BMG Labtech, Ortenberg,
Germany) and used to plot a concentration response curve.
MIC experiments are usually determined based of turbidity of the
solution, however HT61 has been shown to precipitate in CAMH broth
at high concentrations resulting in a high absorbance background.
Therefore we used the metabolic dye Resazurin to overcome this
background precipitation as has been previously reported [19]. Brieﬂy,
Resazurin sodium salt was added to a ﬁnal concentration of 0.15 mM
and plates were incubated for an additional 2–4 h. MICs were then
deﬁned as the lowest concentration inhibiting bacterial activity using
the conversion of resazurin (blue) to resuroﬁn (pink). Experiments were
performed three times in duplicate.
2.4. Synergy assessment by checkerboard assay
The chequerboard method was used for the measurement of po-
tential synergy from combinations of HT61 with tobramycin against
each of the 3 strains of P. aeruginosa as previously described [19,20].
Brieﬂy, the combinations of tobramycin and HT61 were prepared using
96-well plates using drug concentrations starting from 2 fold higher
than their MIC values and then serially diluting 2-fold to zero in sterile
ﬂat well polycarbonate plates (Greiner Bio-One Ltd) to create 64
combinations. The experiment was then performed using the MIC
methodology as described above. The growth/no growth interface was
then determined using the visual colour change of resazurin (blue) in to
the pink resoruﬁn product and used to plot isobolograms and for the
calculation of the fractional inhibitory concentration (FIC) as a measure
of the eﬀects of combination therapies.
The sum of FICs or FIC indexes (FICIs) were calculated as
ΣFICA + B = FICA + FICB where FICA = MICA+B/MICA and
FICB = MICA+B/MICB.
The Loewe additivity theory was used with a lower cut oﬀ to de-
termine synergy [21]. The interaction of the combination was deﬁned
as showing synergy if the FICs were≤0.5, additivity or no interaction if
the FIC was>0.5 but< 4.0 and antagonism if the FIC was> 4.0 [20].
2.5. Synergy assessment by bacterial time kill assays
To investigate any synergistic eﬀects on the rate of killing, time-kill
assays were performed with HT61 and tobramycin as previously de-
scribed [22,23]. Bacteria (5 × 105 cfu/mL) were cultured in 10 mL of
CAMH broth in glass ﬂasks in the presence of tobramycin and/or HT61
at sub-inhibitory concentrations. Cultures were incubated at 37 °C for
24 h under continuous shaking conditions (130 rpm). Bacterial viability
was determined by collecting aliquots at 0, 4, 8, 12 and 24 h. Samples
of bacterial suspensions were then serially diluted in sterile saline and
plated on TSA. Plates were subsequently incubated at 37 °C for 16–18 h,
and colony forming units counted.
2.6. Minimum bioﬁlm concentration eradication assay
Eﬀect of combination therapy was studied on bioﬁlms by using the
Calgary devices as previously described with minor modiﬁcations [24].
One colony was inoculated in CAMH and incubated under continuous
shaking conditions (37 °C, 130 rpm). After approximately 20 h, cells
were washed twice by centrifugation (5,000g, 4°c) and resuspended in
sterile saline. Bacterial suspensions were diluted to 105 cfu/mL in
CAMH and inoculated in a 96 well plate (150 μL per wells). Plate lids
were replaced with the Nunc-TSP 96 Pin lid and bioﬁlms were left to
form for 18–20 h under shaking (110 rpm) in a wet atmosphere. Es-
tablished bioﬁlms on pins were washed with 200 μL of sterile saline and
transferred into a challenge plate. Challenge plates were made of serial
dilutions of tobramycin supplemented with HT61 at 25, 50 and 100 μg/
mL in CAMH (200 μL per wells). For each plate, controls of tobramycin
and HT61 alone were present, as well as sterility controls. Bioﬁlms were
challenged for 18–20 h under the same conditions (37 °C, 110 rpm, wet
atmosphere). Following challenge, bioﬁlms were placed in an inhibitor
free environment (CAMH, 200 μL per wells), left to equilibrate at room
temperature for 30 min and sonicated at high intensity for 30 min.
Sonication eﬃciency was visually checked by crystal violet 0.1%
staining. Recovery plates containing detached bioﬁlms were incubated
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for a further 24–48 h and used to determine MBEC (minimal bioﬁlm
eradication concentration), where an MBEC was deﬁned as the lowest
concentration to inhibit growth as previously recommended.
2.7. Murine model of pulmonary infection
All animal experiments were performed under the authority and
approval of the U.K Home Oﬃce outlined in the Animals (Scientiﬁc
Procedures) Act 1986 with local ethical approval from King's College
London (project license PPL 70/8279).
Bacterial embedded agar beads were prepared using the protocol
described previously [25]. Brieﬂy, bacterial cultures were prepared by
inoculating a TSA plate with a stock cryobead and incubating at 37 °C
for 24 h under static conditions. 24 h prior to use, secondary overnight
cultures were prepared by inoculating 20 ml of TSB with 2–3 bacterial
colonies and subsequently incubated at 37 °C for 16 h under continuous
shaking at 120 rpm. Bacteria were embedded into agar beads by mixing
the secondary overnight culture with molten TSA at a 1:9 ratio, which
was then spun into mineral oil, previously heated to 50 °C. The pre-
paration was cooled and centrifuged at 2700 g and the remaining mi-
neral oil was removed by washing with sterile PBS. Bacterial content of
the beads was then quantiﬁed on TSA plates and diluted to achieve
2 × 107 cfu/mL using sterile PBS, to deliver a ﬁnal dose of 1 × 106 cfu/
mouse.
Animals were housed in ﬁlter top cages under standard conditions
of 22 ± 2 °C with a 12:12 light: dark cycle. All animals were provided
with food and water ad libitum, and wood shavings, shredded paper and
cardboard tubes were provided for environmental enrichment. All an-
imals were provided with a minimum acclimatization period of 7 days
upon arrival before the commencement of the study. Male C57/Bl6J
mice (8 weeks, Harlan, United Kingdom) were anesthetized with in-
haled isoﬂurane and inoculated with 1 × 106 cfu/mouse bacterial
embedded agar beads via oropharyngeal infection (o.a). Sham mice
were inoculated with sterile PBS embedded agar beads via the o.a. route
of administration, as a control. Animals were weighed and monitored
daily for signs of pain and distress. Animals that lost more than 20% of
their body weight throughout the duration of the study were eu-
thanised. 24 h post infection, mice were treated with either saline ve-
hicle, HT61, Tobramycin or a combination treatment of HT61 and
Tobramycin via intraperitoneal (i.p.) injection. 48 h post infection,
lungs were aseptically removed and homogenized in 2 mL sterile saline.
Serial dilutions of lung homogenates were performed, and appropriate
dilutions plated onto TSA plates and incubated for 24 h under static
conditions. Colonies were manually quantiﬁed and log (CFU/mL) cal-
culated.
2.8. Statistical analysis
Chequerboard analysis of synergy was used to identify a fractional
inhibitory concentration (FIC) index, where synergy was determined if
the FIC was≤0.5. Additivity or no interaction was described if the FIC
was>0.5 but< 4.0 and antagonism if the FIC was> 4.0. In vitro Time-
kill analyses of data were presented as mean ± standard error of the
mean (SEM) and analysed by using GraphPad Prism 8.0. Due to ex-
perimental variation, MBEC were expressed as mean of 9–12 replicates.
These data were normally distributed and were therefore eligible for
parametric testing. Diﬀerences between untreated control and each of
the treated groups (25, 50 or 100 μg/mL) were analysed by using an
unpaired student t-test with Welch's correction. The one-way analysis of
variance and Sidak's multiple comparisons post-test were used for
comparisons of data. All in vivo data are presented as mean ± standard
error of the mean of log cfu/ml and analysed using GraphPad Prism 8.0.
The one-way analysis of variance and Sidak's multiple comparisons
post-test were used for comparisons of data. P values of less than 0.05
were determined to demonstrate a signiﬁcant diﬀerence.
3. Results
3.1. Diﬀerences in MIC values for HT61 and tobramycin for strains of P.
aeruginosa
The MICs of HT61 and tobramycin were determined against 3 dif-
ferent strains of P. aeruginosa with diﬀerent susceptibility proﬁles to
tobramcyin. MICs values of HT61 ranged between 50 and 100 μg/ml
against each of the 3 strains (PA01: 100 μg/ml; NN2: 100 μg/ml; RP73:
50 μg/ml, Table 1). Previous research has reported diﬀerential sensi-
tivity of these 3 P.aeruginosa strains to tobramycin, with PA01 reported
as a tobramycin sensitive strain, RP73 reported as a multidrug resistant
strain and NN2 reported as tobramycin resistant [15]. In our studies, in
agreement with the previously reported susceptibility proﬁles, we also
reported marked diﬀerences in the MIC values of tobramycin to each of
these strains with a range of 0.4–100 μg/ml (PA01: 0.4 μg/ml; RP73:
3 μg/ml; NN2: 100 μg/ml, Table 1). HT61 was more eﬀective as de-
monstrated by the smaller MIC in CAMH in comparison to LB and TSB
for all three strains. Similarly, an enhanced susceptibility to tobramycin
was also observed in CAMH for strains PAO1 and RP73.
3.2. Chequerboard analysis revealed HT61 and tobramycin synergy against
P. aeruginosa strains RP73 and NN2
We have previously reported that HT61 demonstrated synergism
against gram-positive bacteria in vitro when used in combination with a
number of aminoglycoside antibiotics, including neomycin, gentamicin
and mupirocin [10]. We therefore extended this work by assessing the
combined activities of HT61 and tobramycin against the 3 strains of
P.aeruginosa. The checkerboard assay was used to assess the eﬀect of
combined tobramycin and HT61 treatment on P. aeruginosa growth,
using 64 combinations of tobramycin and HT61. FICs were determined
by using the growth/no-growth interface. This gave the MIC values for
each agent when used alone and in combination. A representative
image for this can be observed for the multi-drug resistant strain RP73
in Fig. 1A. In this study, synergy was deﬁned as ΣFICs≤0.5 [20].
Fig. 1B demonstrates the FIC indexes for each strain. All details of MICs
and FIC calculations are shown in Supplementary Table 1. The impact
of HT61 and tobramycin interactions was shown to be indiﬀerence/
additive for strain PAO1 (ΣFIC = 0.65 ± 0.073), whilst synergistic for
strains RP73 (ΣFIC = 0.425 ± 0.05) and NN2 (ΣFIC = 0.425 ±
0.073).
3.3. Time-kill analysis reveals synergy between HT61 and tobramycin
against P. aeruginosa strains PAO1, RP73 and NN2
The bactericidal activities of HT61 and tobramycin in combination
were assessed in bacterial time-kill assays over a 24 h timescale. Fig. 2
shows the time kill assay data obtained for P. aeruginosa strains PAO1
(A), RP73 (B) and NN2 (C). HT61 (black squares) and tobramycin
(black circles) were used at subinhibitory concentrations, which did not
signiﬁcantly impact the ﬁnal number of P. aeruginosa cells (growth to
Table 1
P.aeruginosa susceptibility proﬁle to tobramycin and HT61.
P. aeruginosa strain Antibiotic resistance MIC (μg/mL)
Tobramycin HT61
PAO1 Tobramycin sensitive (15) 0.4 100
RP73 Multi resistant (15) 3 50
NN2 Tobramycin resistant (15) 100 100
MIC values derived from dose-response curve data for HT61 and tobramycin
with three strains of P. aeruginosa PA01, RP73 and NN2. Here MIC values are
displayed as μg/ml concentrations. Values were produced from 3 independent
experiments performed in duplicate.
R.T. Amison, et al. Pulmonary Pharmacology & Therapeutics 61 (2020) 101884
3
approximately 10^10 CFU/mL for all strains examined). Assays that
combined both agents at the same concentration are shown as black
triangles. Synergy was subsequently deﬁned as when the diﬀerence in
bacteriasl numbers exceeded two log orders, when comparing a com-
bination of agents to single agents. Strong evidence for synergy was
identiﬁed after 8 h for strain PAO1 (Fig. 2A), with no cfu's detected for
PA01 after 12 h following combination treatment of HT61 and to-
bramycin in comparison to 108 cfu/ml following HT61 monotherapy
and 104 cfu/ml following tobramycin monotherapy at the same time-
point.
For strain RP73 (Fig. 2B), no diﬀerence between HT61 and to-
bramycin monotherapies were observed at any timepoint. However,
combination therapy of HT61 and tobramycin demonstrated a 2 log
fold reduction in recovered bacterial cfu at 8 h (HT61 montherapy:
4.65 × 105 cfu/ml; tobramycin monotherapy: 3.93 × 105 cfu/ml;
combination therapy: 1.2 × 103 cfu/ml) indicating synergy between
the two compounds. The same trend was also observed for the to-
bramycin resistant strain NN2 (Fig. 2C), where no diﬀerence between
HT61 and tobramycin monotherapies were observed, whilst combina-
tion therapy of HT61 and tobramycin once again demonstrated a 3 log
fold reduction in recovered bacterial cfus at 8 h (HT61 montherapy:
3.89 × 105 cfu/ml; tobramycin monotherapy: 8 × 105 cfu/ml; com-
bination therapy: 2 × 102 cfu/ml) from 8 h onwards.
3.4. HT61 signiﬁcantly enhances tobramycin mediated bioﬁlm eradication
Since P. aeruginosa infections are typically associated with bacteria
persisting as bioﬁlms, the impact of combinations of HT61 and to-
bramycin was also investigated on these structured forms of growth.
Firstly, we investigated whether bioﬁlm establishment in vitro was af-
fected by singular treatment with either HT61 or tobramycin through
the checkerboard assay system. In our studies we observed similar FICs
values similar to those produced in the non-bioﬁlm grown samples(data
not shown).
Secondly, we aimed to investigate the eﬀect of tobramycin and
HT61 on already established bioﬁlms. Bioﬁlms, formed in inhibitor free
Fig. 1. Checkerboard assessment of synergy between HT61 and tobramycin
Synergy as shown in an example (strain RP73) of the checkerboard assay (A) and the mean FICIs for the three strains tested (B). Each plate contained two control
wells; a negative (inhibitor on its own) and a positive control (no inhibitor). Negative controls or NC, containing no bacterial cells, were also included. Resazurin was
used to determine the growth-no growth interface as shown by pink wells (alive and active cells) or blue wells (no dye conversion). MICs for agents alone or in
combination were determined and used to calculate FICIs (B). FICIs are shown as the mean of 5 independent experiments, bar represents SEM.
Fig. 2. Time kill assay demonstrating synergy between tobramycin and HT61 against P. aeruginosa.
Eﬀect of sub-inhibitory concentrations of tobramycin (•), HT61 (■) and combination (▲) on the viability of P. aeruginosa strains PAO1 (A), RP73 (B) and NN2 (C).
Samples were taken for enumeration at 0, 4, 8, 12 and 24 h and number of live bacterial cells were plotted as log10. (CFU/mL). Results are the mean of two
independent experiments, bars show SEM.
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conditions, were challenged with tobramycin and HT61. The period of
recovery required was used to determine the minimum bioﬁlm eradi-
cation concentration (MBEC). HT61 given as a monotherapy had no
impact on bacterial cell numbers in previously established bioﬁlm
structures (data not shown). As such, the impact of diﬀerent con-
centrations of tobramycin in the presence of ﬁxed levels of HT61 (25,
50 or 100 μg/mL) was assessed (Fig. 3). For all strains tested, the ad-
dition of HT61 signiﬁcantly enhanced the ability of tobramycin to
eradicate bioﬁlm located cells, as shown by the decreased MBEC. For
strain PAO1 (Fig. 3A), the lowest concentration of tobramycin required
to eradicate bioﬁlms was 43.75 ± 4.49 μg/mL. The addition of 25, 50
or 100 μg/mL of HT61 signiﬁcantly reduced this MBEC to
26.56 ± 4.49 μg/mL (p < 0.05), 15.89 ± 2.48 μg/mL and
15.36 ± 2.59 μg/mL respectively (p < 0.0001). For strain NN2
(Fig. 3B), MBEC for tobramycin alone was above 25 g/L. As the solu-
bility limit was reached, tobramycin MBEC was assumed to be 50 g/L
for those replicates. The tobramycin MBEC alone was therefore esti-
mated at 43.75 ± 3.26 g/L, which was signiﬁcantly reduced
(p < 0.0001) by at least 4-fold when HT61 was added
(10.94 ± 1.56 g/L, 9.90 ± 1.14 g/L, 6.77 ± 0.85 g/L). The strongest
level of enhancement on bioﬁlm eradication was observed with RP73
(Fig. 3C). When used as a single agent, 200 μg/mL tobramycin was
required to eradicate RP73 bioﬁlm structures, whilst HT61 at 25, 50 or
100 μg/mL was shown to lower the tobramycin MBEC to
53.75 ± 10.87 μg/mL (3.7 fold), 33.13 ± 6.91 μg/mL (6-fold) and
25.0 ± 6.04 μg/mL (8-fold) respectively.
3.5. HT61 showed no bactericidal activity against any tested bacterial
strain in vivo
The in vitro data described in sections 3.1-3.4 described an ability of
HT61 to enhance the activity of tobramycin against both RP73 and
NN2. We therefore investigated whether this enhancement was re-
plicated in in vivo studies using a murine model of pulmonary infection
with P. aeruginosa. Dose-response titrations of HT61 were performed
towards infections with all three strains of P. aeruginosa described
above, in order to determine whether HT61 monotherapy demonstrated
any bactericidal activity in vivo. In all studies, inoculation with
1 × 106 cfu RP73/NN2/PA01 per mouse resulted in signiﬁcant in-
creases in bacterial cell numbers when compared to sham controls
(Sham: 0.00 ± 0.00 log cfu/ml vs. RP73: 6.16 ± 0.22 log cfu/ml,
P < 0.001; NN2: 4.85 ± 0.18 log cfu/ml, P < 0.001; PA01:
5.90 ± 0.03 log cfu/ml, P < 0.001, Fig. 4A–C). Single systemic
treatment with 0.1, 1 and 5 mg/kg HT61 i.p. failed to demonstrate any
reduction in pulmonary bacterial load when compared to vehicle
treated controls at 48 h against any of the three P. aeruginosa strains
tested; RP73 (Vehicle: 6.16 ± 0.22 log cfu/ml vs 0.1 mg/kg:
5.91 ± 0.12 log cfu/ml; 1 mg/kg: 6.45 ± 0.12 log cfu/ml; 5 mg/kg:
6.64 ± 0.41 log cfu/ml), NN2 (Vehicle: 4.85 ± 0.18 log cfu/ml vs
0.1 mg/kg: 5.34 ± 0.32 log cfu/ml; 1 mg/kg: 5.12 ± 0.43 log cfu/ml;
5 mg/kg: 5.80 ± 0.69 log cfu/ml) or PA01 (Vehicle: 5.90 ± 00.03 log
cfu/ml vs 0.1 mg/kg: 6.73 ± 0.20 log cfu/ml; 1 mg/kg: 5.74 ± 0.14
log cfu/ml; 5 mg/kg: 5.74 ± 0.33 log cfu/ml). This suggested that
unlike in previous studies performed against gram-positive bacteria,
HT61 has no direct anti-bacterial activity against gram-negative P.aer-
uginosa.
3.6. HT61 signiﬁcantly enhanced the eﬃcacy of tobramycin against the P.
aeruginosa strains RP73, NN2 and PA01 in vivo
Our in vitro experiments demonstrated clear synergy between HT61
and tobramycin when used as a combination therapy against P. aeru-
ginosa strains RP73 and NN2, but not PA01. We therefore subsequently
assessed whether this in vitro ﬁnding could be translated in vivo using a
murine model of pulmonary infection.
Initial dose-response experiments were performed to identify a sub-
threshold dose of tobramycin which failed to reduce bacterial numbers
retrieved from the lungs 48 h post infection when compared to vehicle
controls (Supplementary Fig. 1). From these experiments, 100 mg/kg
systemic tobramycin was selected for the drug resistant P. aeruginosa
strains RP73 and NN2, whilst 50 mg/kg was selected for P. aeruginosa
reference strain PA01.
In the ﬁrst series of the combination studies, mice were con-
comitantly treated with subthreshold tobramycin doses as previously
identiﬁed and 1 mg/kg HT61. Supporting our earlier in vitro and in vivo
experiments described above, treatment with 1 mg/kg HT61 alone
demonstrated no reduction in bacterial numbers 48 h post treatment
when compared to vehicle for RP73 (Vehicle: 5.54 ± 0.01 log cfu/ml
vs 1 mg/kg HT61: 5.65 ± 0.01 log cfu/ml), NN2 (Vehicle:
6.59 ± 0.21 log cfu/ml vs 1 mg/kg HT61: 6.54 ± 0.20 log cfu/ml) or
PA01 (Vehicle: 4.70 ± 0.13 log cfu/ml vs 1 mg/kg HT61:
4.97 ± 0.06 log cfu/ml). Furthermore, monotherapy with the sub-
threshold dose of tobramycin had no eﬀect on bacterial numbers when
compared to vehicle for RP73 (Vehicle: 5.54 ± 0.01 log cfu/ml vs
100 mg/kg tobramycin: 5.56 ± 0.01 log cfu/ml), NN2 (Vehicle:
6.59 ± 0.21 log cfu/ml vs 100 mg/kg tobramycin: 6.24 ± 0.24 log
cfu/ml) or PA01 (Vehicle: 4.70 ± 0.13 log cfu/ml vs 50 mg/kg
Tobramycin: 5.06 ± 0.11 log cfu/ml) (Fig. 5A and B). However, when
mice were treated with a combination of both 1 mg/kg HT61 and to-
bramycin, a signiﬁcant reduction in bacterial numbers was observed
Fig. 3. HT61 reduces the tobramycin concentration required to eradicate established bioﬁlm (MBEC)
Eﬀect of ﬁxed doses of HT61 (25, 50 or 100 μg/mL) on tobramycin MBEC on P. aeruginosa strain PAO1 (A), NN2 (B) or RP73 (C). MBEC were determined as the
lowest concentration of tobramycin to inhibit bacterial recovery after antibacterial challenge of established bioﬁlms. Data are expressed as mean of MBEC
(n = 9–12), bars represent SEM. *P < 0.05 and ****P < 0.0001 non-treated control vs HT61 at 25, 50 or 100 μg/mL (unpaired student t-test with Welch's
correction).
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against the multi-drug resistant strain RP73 (Vehicle: 5.54 ± 0.01 log
cfu/ml vs 1 mg/kg HT61 + 100 mg/kg Tobramycin: 4.51 ± 0.12 log
cfu/ml, P < 0.001) and the tobramycin resistant strain NN2 (Vehicle:
6.59 ± 0.21 log cfu/ml vs 1 mg/kg HT61 + 100 mg/kg tobramycin:
5.49 ± 0.33 log cfu/ml, P < 0.05). In contrast, this ﬁnding was not
observed for the tobramycin sensitive strain PA01 (Vehicle:
4.70 ± 0.13 log cfu/ml vs 1 mg/kg HT61 + 50 mg/kg tobramycin:
5.00 ± 0.06 log cfu/ml) (Fig. 5C).
Next, we investigated whether the inability of HT61 to potentiate
the activity of tobramycin against PA01 was due to an insuﬃcient dose
of HT61 used in the combination treatments. We therefore replicated
the above studies using an increased 10 mg/kg dose of HT61 in the
combination treatment with tobramycin. With this increased dose of
HT61, we observed signiﬁcant reductions in pulmonary bacterial
numbers against vehicle control mice 48 h post infection with all
strains, RP73 (Vehicle: 4.81 ± 0.25 log cfu/ml vs 10 mg/kg
HT61 + 100 mg/kg tobramycin: 2.57 ± 0.36 log cfu/ml, P < 0.001),
NN2 (Vehicle: 4.49 ± 0.14 log cfu/ml vs 10 mg/kg HT61 + 100 mg/
kg tobramycin: 3.74 ± 0.31 log cfu/ml, P < 0.05) and PA01 (Vehicle:
4.96 ± 0.11 log cfu/ml vs 10 mg/kg HT61 + 50 mg/kg tobramycin:
3.41 ± 0.46 log cfu/ml, P < 0.05) (Fig. 6A–C).
We were interested as to whether or not the signiﬁcant reductions
observed in vivo by combining HT61 with tobramycin was due to an
additive eﬀect or due to synergistic interactions between the two drugs.
We therefore calculated the expected reductions in bacterial numbers if
it were due to an additive eﬀect (Supplementary Table 2). Here, the
reductions in bacterial numbers observed for all 3 strains suggested the
possibility that a greater than additive eﬀect was observed between
HT61 and tobramycin, which supported our in vitro data.
4. Discussion
The properties of compounds such as HT61 have been of growing
interest in terms of clinical utility. In this study, we found that HT61
had little or no discernable antibacterial activity against the gram-ne-
gative pathogen P. aeruginosa in contrast to the previously described
activity observed against gram-positive bacteria [11]. However, the key
ﬁndings of this study were the identiﬁcation of signiﬁcant synergistic
activities between HT61 and the classical aminoglycoside antibiotic
tobramycin against P. aeruginosa. These ﬁndings have a particular
bearing in terms of the clinical management of airway infection by P.
aeruginosa for individuals with CF. Whilst novel therapies are emerging
that address the fundamental genetic defect associated with CF, it is
equally important to improve existing antibiotic approaches towards
the clearance of chronic infections by this pathogen, particularly in
patients colonized with strains resistant to treatment with antibiotics.
In this study, 3 diﬀerent strains of P. aeruginosa were considered
including the multi-drug resistant (RP73) and tobramycin resistant
(NN2) strains [15] alongside PAO1 as a reference laboratory strain. As
such, these strains represented a range of known phenotypic responses
to tobramycin. The observation that HT61 in combination with to-
bramycin produced a synergistic eﬀect in vitro against the strains con-
sidered as resistant to tobramycin was therefore encouraging. In turn,
this provided a strong rationale for the assessment of the antibacterial
activity of combinations of HT61 and tobramycin in vivo using a murine
model of pulmonary infection. As such, our observations have extended
previous work with HT61 where this small quinolone derived com-
pound has demonstrated activity against gram-positive species, in-
cluding Staphylococcus aureus (both MSSA and MRSA) in vitro and in a
Fig. 4. Eﬀect of single treatment of HT61 against P. aeruginosa in a murine model of pulmonary infection
Mice were infected with either sterile PBS embedded agar beads, 1 × 106 cfu/mouse P. aeruginosa strains RP73 (A), NN2 (B) or PA01 (C), embedded agar beads, via
o.a. inoculation. 24 h post infection, mice were administered with either vehicle, 0.1, 1 and 5 mg/kg HT61 via intraperitoneal injection. 48 h post infection, colony
forming units were quantiﬁed in lung homogenate on TSA plates. n = 3–5, data expressed as log mean ± SEM. ***P < 0.001 versus sham control mice.
LOD = Limit of Detection. Data analysed using one-way ANOVA and Sidak's multiple comparisons post-test.
Fig. 5. Eﬀect of combination treatment of 1 mg/kg HT61 and tobramycin against P. aeruginosa in a murine model of pulmonary infection
Mice were infected with either sterile PBS embedded agar beads, 1 × 106 cfu/mouse P. aeruginosa strains RP73 (A), NN2 (B), PA01 (C) embedded agar beads, via o.a.
inoculation. 24 h post infection, mice were administered with either vehicle, tobramycin (100 mg/kg) and HT61 (1 mg/kg) as single treatments, or combination
treatments 100 mg/kg tobramycin +1 mg/kg HT61 via intraperitoneal injection. 48 h post infection, colony forming units were quantiﬁed in lung homogenate on
TSA plates. n = 4–5, data expressed as log mean ± SEM. ###P < 0.001 versus vehicle, #P < 0.05 versus vehicle. LOD= Limit of Detection. Data analysed using
one-way ANOVA and Sidak's multiple comparisons post-test.
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wound infection model [10,11,26,27]. Importantly, in these studies
HT61 was also observed to enhance the bactericidal activity of existing
antibiotics including gentamicin and neomycin against both MSSA and
MRSA in addition to its own individual bactericidal capabilities
[11,28]. Extending from these studies our focus here was on P. aeru-
ginosa, which demonstrates signiﬁcant resistance to current therapy.
The ﬁnding in this study that both a tobramycin resistant and multi-
drug resistant strain of this species were rendered sensitive – as if “re-
stored” – was therefore a novel and exciting ﬁnding and the potential
clinical beneﬁts of such a ﬁnding are clear. Through the identiﬁcation
of the requirement of HT61 in this combinational role, we propose this
class of antibacterial agent as an enhancer of the eﬃcacy and impact of
conventional antibiotics, and therefore propose the deﬁnition of ‘anti-
biotic enhancer’ as a substance that in relatively low concentrations
extends the antibacterial activity of a conventional antibiotic, despite
having no or low-level antibacterial activity in itself.
Given the concern over the lack of novel antibiotics in the pipeline,
alternate strategies designed to maximise and enhance the activity and
in turn longevity of existing antibiotics are important. Borrowing the
same terminology as for antibiotic susceptibility, enhancers could ei-
ther be narrow or broad in their spectrum. The ability of HT61 to render
RP73, a nearly tobramycin resistant strain (MIC of 3 μg/mL), suscep-
tible to tobramycin therapy (MIC reduced to 0.6 μg/mL), both in vitro
and in vivo is therefore highly important. Such enhancer strategies
would avoid scenarios whereby resistance to an antibiotic is overcome
by simply increasing the dose of the antibiotic prescribed. This is of
particular relevance for aminoglycosides such as tobramycin, as it is
neither feasible or ethical to signiﬁcantly increase the doses used due to
their systemic toxicity proﬁles, as in addition to their ototoxic and
nephrotoxic side eﬀects, chronic kidney disease has also been asso-
ciated with chronic tobramycin treatment, in individuals with cystic
ﬁbrosis [29–32]. As an alternative to simply increasing antibiotic
plasma levels, the use of multiple antibiotics in combination has been
proposed as a strategy capable of slowing the emergence of anti-
microbial resistance whilst also shortening the required duration of
therapy [33]. Antibiotics from a number of diﬀerent classes have pre-
viously been reported to show synergistic eﬀects against tobramycin
resistant strains of P. aeruginosa [34], therefore enhancer strategies (or
antibiotic resistance breakers), featuring low or no direct antibiotic
impact, may be less susceptible as a target for resistance emergence and
could be a viable alternative approach [35,36].
Resistance, emerging or intrinsic, is a feature of the pathogen P.
aeruginosa [37]. Despite the layered nature of the resistance char-
acteristic of P. aeruginosa, compounds able to compromise the integrity
of bacterial cell membranes are likely to enhance antibiotic penetration.
The mechanism by which HT61 may enhance the activity of classical
antibiotics is through its non-speciﬁc targeting of anionic lipids in the
bacterial membrane due to the negative charge of HT61. In the case of
S. aureus such anionic lipids may include phosphatidylglycerol (PG) and
the zwitterionic phosphatidylethanolamine [12,13]. In targeting these
lipids, HT61 induces rapid partitioning of the lipid bilayer into a
monolayer causing structural changes thus impairing membrane in-
tegrity leading to depolarisation and catastrophic membrane damage
[12,13]. In contrast to previous studies, where HT61 has shown bac-
tericidal activity against strains of S. aureus [10,11], HT61 treatment as
a monotherapy had little or no bactericidal eﬀects on any of the tested
strains of P. aeruginosa in any of our in vitro or in vivo models. This may
be due to diﬀerences in the membrane lipid composition between the
two species [38,39] with cationic membrane acting agents such as
HT61 showing greater activity against S. aureus [40].
Using a pharmacodynamic model, Bulitta et al. accounted for two
killing mechanisms associated with aminoglycoside use against P. aer-
uginosa [41]. Delayed killing was attributed to the eﬀect of tobramycin
on bacterial protein synthesis whilst immediate killing was attributed to
disruption of the outer membrane [41]. It is possible that our ob-
servation of increased tobramycin activity when combined with HT61
is as a result of the initial disruption of the outer membrane by to-
bramycin increasing the exposure of the anionic phospholipids on the
inner cytoplasmic membrane to HT61. The resulting disruption of both
membranes would increase the permeability of the gram-negative
bacterial membranes to tobramycin, resulting in an elevated in-
tracellular tobramycin concentration enhancing the bactericidal ac-
tivity through its eﬀects on protein synthesis [10,11]. Whilst the me-
chanism of action of HT61 remains open for discussion and further
studies are required to fully understand the mechanism of action of
HT61 in the potentiation of tobramycin against gram-negative bacteria,
it is also important to consider the impact on the mode of growth of P.
aeruginosa. Here, the impact on bioﬁlm formation, as well as the impact
of HT61/tobramycin on existing bioﬁlms was also examined. Whilst
HT61 had no impact on either establishing or established bioﬁlm
structures in our tested concentration range, when treated in combi-
nation with tobramycin we demonstrated a 10-fold reduction in the
MBEC observed with tobramycin alone.
These studies therefore demonstrate an exciting enhancement of
tobramycin's activity; however, we acknowledge that whilst our studies
used an extended range of assays, the ﬁndings are limited by the as-
sessment of a single antibiotic. Whilst we used three individual strains
of P. aeruginosa covering a range in susceptibility to a tobramycin the
assessment of HT61's ability to enhance the bactericidal activity of
additional antibiotics would further strengthen the ﬁndings detailed in
this study.
In conclusion, the combination of tobramycin with HT61 demon-
strated signiﬁcant potentiation of bactericidal activity when compared
to tobramycin as a monotherapy against both tobramycin sensitive and
resistant strains of P. aeruginosa, in both in vitro assays and an in vivo
model of lung infection. This indicates the potential beneﬁts of
Fig. 6. Eﬀect of combination treatment of 10 mg/kg HT61 and tobramycin against P. aeruginosa in a murine model of pulmonary infection
Mice were infected with either sterile PBS embedded agar beads, 1 × 106 cfu/mouse P. aeruginosa strains RP73 (A), NN2 (B) or PA01 (C) embedded agar beads, via
o.a. inoculation. 24 h post infection, mice were administered with either vehicle, tobramycin (100 mg/kg) and HT61 (10 mg/kg) as single treatments, or combination
treatments 100 mg/kg tobramycin +10 mg/kg HT61 via intraperitoneal injection. 48 h post infection, colony forming units were quantiﬁed in lung homogenate on
TSA plates. n = 4–5, data expressed as log mean ± SEM. versus sham control mice, ###P < 0.001 versus vehicle, #P < 0.05 versus vehicle, δ P < 0.05 vs 1 mg/
kg HT61. LOD = Limit of Detection. Data analysed using one-way ANOVA and Sidak's multiple comparisons post-test.
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combination treatments using enhancer compounds, such as HT61
alongside conventional antibiotics including tobramycin in the treat-
ment of antibiotic resistant gram-negative infections. Such enhancer
strategies would support the use of lower doses of the aminoglycoside
antibiotics signiﬁcantly reducing their associated toxicity proﬁles thus
providing a potentially novel way of targeting the ongoing global issue
of antimicrobial resistance.
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